Generic Evista online and prices from India. Worldwide shipping, including USA, Australia, Canada, UK, Mexico...

EVISTA

Evista - raloxifene - is prescribed to treat and prevent osteoporosis, the brittle-bone disease that strikes some women after menopause. Estrogen is a hormone which among other actions, regulates the turnover (formation and destruction) of bone. Decreases in estrogen levels that are seen after menopause or after removal of the ovaries, lead to a loss of bone density and weakened bones, a condition called osteoporosis. Raloxifene decreases bone turnover and increases bone density although not to the same extent as estrogen itself. This makes bones stronger and prevents fractures in women with osteoporosis. Raloxifene is called a "selective estrogen receptor modulator" since it has effects like estrogen on some tissues but inhibits the effects of estrogen on other tissues. Raloxifene decreases low density lipoprotein (LDL or "bad") cholesterol in the blood; however, unlike estrogen, raloxifene does not increase high density lipoprotein (HDL or "good") cholesterol. Evista does not have estrogen-like effects on the uterus and breasts, and therefore is unlikely to increase the risk of cancer, as estrogen therapy sometimes can do.

SIDE EFFECTS: The most common side effects with Evista are hot flashes (seen in 1 of every four persons), sinusitis (1 in 10), weight gain (1 in 11), muscle pain (1 in 12), leg cramps (1 in 20), and ankle swelling (1 in 30).

Raloxifene increases the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (blood clots in the lung). The greatest increase in risk occurs during the first 4 months of use. Patients taking raloxifene should avoid prolonged periods of restricted movement during travel when blood clots are more prone to occur.